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The discovery of mutations in calreticulin (CALR) in patients with
primary myelofibrosis (PMF)1,2 prompted a reappraisal of the
clinical correlates and prognostic impact of the so-called driver
mutations that include JAK2V617F, MPLW515L/K/A and CALR in
~ 60%, 5–10% and 20–25% of patients, respectively. As compared
with their JAK2V617F counterpart, PMF patients harboring CALR
mutations showed younger age, higher platelet and lower
hemoglobin and leukocyte counts. The cumulative incidence of
anemia, leukocytosis and thrombocytopenia was significantly
lower in CALR-mutated patients who were also less likely to be
red cell transfusion-dependent;3,4 in addition, they had signifi-
cantly longer large splenomegaly-free survival compared with
the other genotypes as well as patients lacking the three
driver mutations (triple-negative (TN) patients).3,4 Interestingly,
spliceosome mutations were significantly less represented in
CALR-mutated patients; however, no additional molecular or
cytogenetic correlate was highlighted.3 These data suggested a
milder disease in patients harboring the CALR mutation, and
conceivably the presence of CALR mutation was associated with
better overall survival (OS) when compared with JAK2V617F- and
MPLW515-mutated patients, and particularly TN patients.3,4
In multivariable analysis, CALR mutations had a favorable impact
on survival that was independent of International Prognostic
Scoring System (IPSS), Dinamic IPSS (DIPSS)4 or DIPSS-plus risk
stratification,3 and also of ASXL1 mutation, known for its dismal
impact on survival in PMF.5 At this regard, we found that DIPSS-
plus-independent OS was significantly longer in CALR-mutated/
ASXL1-unmutated compared with CALR-unmutated/ASXL1-mutated
patients.6
Two main types of CALR mutations have been described until
now, known as type 1 (a 52-bp deletion; p.L367fs*46) and type 2
(a 5-bp TTGTC insertion; p.K385fs*47); more than 50 indels were
subsequently reported that can be grouped as type 1- or type
2-like based on their molecular characteristics. The frequency of
type 1 mutation is reported to be higher in PMF (60–80%)4,7
compared with essential thrombocythemia (39–61%),4,8–11 a part
for a series including Chinese patients where no difference was
noticed.12 Interestingly, known mutations generate a novel amino-
acid C terminus of the protein with loss of the KDEL motif and
replacement of negatively with positively charged or neutral
amino acids, whose proportion however varies according to the
type of mutation and might underlie emerging differences in the
clinical correlates and prognostic impact associated with the two
types of mutations. In this regard, it has been shown recently that
the phenotype of mice expressing type 1 or type 2 mutation by
retroviral transfer differs in that type 1 was associated with marked
thrombocytosis and rapid progression to a myelofibrosis-like
disease (with subsequent thrombocytopenia, splenomegaly and
anemia), whereas type 2 was a milder phenotype with less
thrombocytosis and reduced propensity to evolve.13 In a study of
617 PMF patients, of whom 140 were CALR-mutated, we found
that patients harboring type 1 CALR mutation (n= 101) had a
better OS compared with those harboring JAK2V617F mutation
(n= 399; Po0.001), whereas no difference was observed between
CALR type 1 and type 2 (n= 22), and as well as between patients
with CALR type 2 mutation and those with JAK2V617F; such
differences remained also after adjustment for the DIPSS score.4
A significant impact of CALR type 1 versus type 2 was observed by
Tefferi et al.7 in a comparison of 76 and 10 CALR-mutated patients,
respectively, that also included 196 patients harboring JAK2V617F
mutation. Survival was longer in CALR type 1 compared with both
CALR type 2 (hazard ratio (HR) 2.5, 95% confidence interval (CI)
1.1–5.4) and JAK2V617F (HR 2.8, 95% CI 1.9–4.2); in multivariable
analysis that included DIPSS and ASXL1 mutational status,
JAK2V617F versus CALR type 1 mutation, DIPSS and ASXL1 all
remained independently predictive of shortened survival. At
variance with the above results, a shorter survival associated with
CALR type 1 mutation (HR 36.3, 95% CI 4.0–324.7) was reported by
Cabagnols et al.11 in a study that included 45 type 1 and 8 type 2
PMF patients. On the other hand, by comparing 98 type-1/type 1-
like with 15 type 2/type 2-like CALR-mutated patients, Tefferi
et al.14 showed that the median survival of type 1/type 1-like
patients (13.7 years) was significantly better than type 2/type 2-
like (3.5 years) ones, that on turn had survival superimposable to
patients harboring JAK2V617F mutation (4 years). The difference
between the two types of CALR mutation remained significant
after adjusting for age, ASXL1 or EZH2 mutations.
Owing to the above conflicting results, the aim of this study was
to evaluate the prognostic impact, if any, of the two different
types of CALR mutations in a series of 396 PMF patients with a
diagnosis of PMF made according to the 2008 World Health
Organization criteria seen in our center. The mutational status of
CALR was determined at diagnosis using previously described
procedure of high-resolution capillary electrophoresis of fluores-
cent dye-labeled PCR amplicon of CALR exon 9;1 samples with
abnormal peaks were subjected to conventional bidirectional
Sanger sequencing. The mutated CALR allelic burden was
estimated by peak area integration from capillary electrophoresis
plot. The JAK2V617F mutational status was determined using
real-time polymerase chain reaction, as described.15 Comparisons
of quantitative variables between groups of patients were carried
out using the nonparametric Wilcoxon rank-sum test. The
cumulative probability of survival (OS) was estimated using
the Kaplan–Meier method. Differences in OS between the groups
were compared by using a log-rank test in univariate analysis. The
SPSS package (V.22; Chicago, IL, USA) was used for statistical
analysis.
Out of the entire series, we found 251 patients (63.4%)
harboring JAK2V617F mutation, 21 (5.3%) with a MPLW515
mutation, 50 (12.6%) lacking any known driver mutation and 74
(18.7%) who harbored a CALR mutation, of whom 53 (71.6%) were
type 1/type 1-like and 21 (28.4%) were type 2/type 2-like. There
was no statistically significant difference between the two groups
harboring CALR mutation as regards the various hematologic and
clinical variables reported in Table 1. On the other hand, patients
harboring both CALR mutation types differed from the JAK2V617F-
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mutated counterpart for younger age, lower leukocyte and higher
platelet counts; males were more represented among Type 1/type
1-like patients than the other genotypes. The risk stratification of
the patients was performed using the IPSS score at the time of
diagnosis, coincident with the genotyping. There were less IPSS
intermediate-2 and high-risk patients in CALR type 1/type 1-like
mutational group (20.8%) as compared with type 2/type 2-like
(38%; P= 0.04) and JAK2V617F mutational groups (44.2%;
P= 0.193).
One hundred three patients died (26.0% of total), accounting
for 17%, 47.6% and 33.5% of the patients harboring CALR type
1/type 1-like, CALR type 2/type 2-like and JAK2V617F mutation,
respectively. The difference was statistically significant for the
comparison of type 1/type 1-like versus both type 2/type 2-like
(P= 0.007) and JAK2V617F (P= 0.011), unlike for type 2/type 2-like
versus JAK2V617F mutation (P= 0.142). Kaplan–Meier estimates of
survival are shown in Figure 1. The median survival of patients
harboring CALR type 1/type 1-like mutation was 26.4 years (range,
15.5–37.3) versus 7.4 years (4.6–10.2) for CALR type 2/type 2-like
and 7.2 years (5.7–8.6) for JAK2V617F. The difference between
type 1/type 1-like and the other two groups was highly significant
(Po0.0001). The corresponding HR (95% CIs), taking the
CALR type 1/type 1-like group as the reference, was 4.9 (95% CI,
1.8–12.9) and 6.0 (95% CI, 2.7–13.4) for CALR type 2/type 2-like and
JAK2V617F-mutated patients, respectively. Survival of patients
with CALR type 2/type 2-like mutation did not differ from
MPLW515-mutated patients (n= 21; median survival 14.7 years;
HR 6.0, 95% CI, 2.2–16.3), whereas, as previously reported, the
worst survival (median, 2.0 years; 1.6–2.4) was observed in TN
patients (HR 20.6, 95% CI, 8.9–48.4). In a multivariable Cox
proportional hazard regression model considering type of
mutation (CALR type 1/1-like, CALR type 2/2-like and JAK2V617F)
and the IPSS score, CALR type 2/type 2-like (HR 4.4, 95% CI 1.6–11.7)
and JAK2V617F (HR 3.8, 95% CI 1.7–8.7) retained significant
IPSS-independent prognostic impact on survival. Finally, there
were more leukemia transformations in CALR type 2/type 2-like
mutational group than in type 1/type 1-like (19 versus 5.7%) and
JAK2V617F (6.8%) one; however, the low number of events
warrants caution in the interpretation of the data.
In summary, our findings support previous report that the
prognostic advantage of CALR mutation in PMF regards only
patients harboring type 1/type 1-like mutation, as the survival of
those harboring type 2/type 2-like mutation does not differ from
JAK2V617F-mutated patients. However, even this study, although
including the highest number of patients to date, suffers from a
relatively small number of CALR type 2/type 2-like mutated cases,
which might hamper a clean understanding of the relevance of
Table 1. Clinical characteristics and outcome of PMF patients stratified according to their CALR type 1/type 1-like, CALR type 2/type 2-like and
JAK2V617F mutational status
Variables CALR mutated JAK2V617F
mutated
P-value






N (% of total) 53 (13.4%) 21 (5.3%) — 251 (63.4%) — — —
Age in years; median (range) 53.3 (21–84) 61.2 (27–82) 0.210 66.7 (28–90) o0.0001 o0.0001 0.027
Males; n (%) 25 (47.2%) 13 (61.9%) 0.253 159 (63.3%) 0.090 0.022 0.534
Hemoglobin, g/l; median (range) 112 (64–140) 108 (80–150) 0.958 120 (40–175) 0.637 0.362 0.704
Leukocytes, × 109/l; median (range) 7.0 (1.6–18.9) 7.7 (4.2–18.1) 0.159 10.0 (1.9–96.2) o0.0001 o0.0001 0.047
Platelets, × 109/l; median (range) 441.5 (59–1563) 629.5 (22–1302) 0.112 308.0 (23–2011) o0.0001 0.024 o0.0001
Circulating blasts ⩾ 1%; n (%) 6 (12.8%) 5 (27.8%) 0.149 45 (18.7%) 0.356 0.227 0.252
Constitutional symptoms; n (%) 14 (26.4%) 4 (19.0%) 0.505 93 (37.1%) 0.106 0.093 0.074
Cytogenetic categories; n (%)
’N’ evaluable = 231
Abnormal
Unfavorable karyotype
7 (22.6%) 3 (23.1%) 0.971 45 (30.6%) 0.267 0.286 0.171
High/very high 4 (12.9%) 2 (15.4%) 0.827 16 (10.9%) 0.858 0.474 0.444
IPSS risk group; n (%)
Low 26 (49.0%) 9 (43.0%) 0.170 58 (23.1%) 0.001 o0.0001 0.193
Intermediate-1 16 (30.2%) 4 (19.0%) 82 (32.7%)
Intermediate-2 9 (17.0%) 4 (19.0%) 56 (22.3%)
High 2 (3.8%) 4 (19.0%) 55 (21.9%)
Progression to leukemia; n (%) 3 (5.8%) 4 (19.0%) 0.08 17 (6.8%) 0.105 0.540 0.066
Death; n (%) 9 (17.0%) 10 (47.6%) 0.007 84 (33.5%) 0.017 0.011 0.142
Abbreviation: PMF, primary myelofibrosis. Bold values denote statistically significant difference.
Figure 1. Survival data of PMF patients stratified according to their
CALR type 1/type 1-like, CALR type 2/type 2-like and JAK2V617F
mutational status.
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such mutational status for survival; furthermore, the mutational
landscape of PMF is highly complex because of the occurrence of
several other subclonal mutations that exert a strong prognostic
impact, which should be taken into an account. Therefore, larger
patient series and inclusion of as many as possible mutational data
in a multivariable model are needed before such information can
be translated to the clinical practice to inform therapy.
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